Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Cyril V. Abobo"'
Publikováno v:
British Journal of Pharmacology. 168:1851-1858
Background and Purpose Warfarin is often used with etravirine (ETV) to prevent HIV-related thromboembolic events. As both warfarin and ETV bind to plasma proteins and are metabolized by hepatic cytochrome P450s, they are likely to interact. Hence, we
Publikováno v:
Nicotine & Tobacco Research. 14:801-808
Introduction The effect of menthol on nicotine disposition is important in understanding smoking behaviors among different racial groups. The present study was to evaluate whether menthol affects the pharmacokinetics of nicotine after cigarette smoke
Publikováno v:
Aviation, Space, and Environmental Medicine. 83:8-13
Background Gender differences in gastrointestinal physiology and hepatic metabolizing enzyme systems may potentially modify drug absorption and disposition during spaceflight. This study evaluated the effect of simulated weightlessness on gender-rela
Publikováno v:
Journal of Chromatography B. 878:3181-3186
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is active against NNRT-resistant HIV-1. A simple, sensitive, and specific LC-MS/MS method was developed and validated for the analysis of etravirine in rat plasma using itrac
Publikováno v:
American Journal of Health-System Pharmacy. 66:1105-1109
Purpose. The stability of extemporaneously prepared oral suspensions of zonisamide at room temperature and under refrigeration is evaluated. Methods. Simple-syrup and methylcellulose (0.5%) suspensions of zonisamide (10 mg/mL) were prepared using com
Autor:
Jyothy John, Keila Robinson, Cyril V. Abobo, Mathew John, Jason Caballero, Dong Liang, Jing Ma
Publikováno v:
Tandem Mass Spectrometry-Applications and Principles
Warfarin, one of the most commonly used oral anticoagulant in the US and across the globe, is a drug of choice for millions. It’s a unique drug of its kind due to the multiple pharmacological and pharmacokinetic properties. The posology of warfarin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f72c3931581235f4d47b322e45172fb
https://doi.org/10.5772/32204
https://doi.org/10.5772/32204
Publikováno v:
American Journal of Health-System Pharmacy. 47:1659-1679
Publikováno v:
Journal of pharmaceutical sciences. 83(1)
Although several drugs have shown clinical anti-human immunodeficiency virus activity, reduced activity with long-term use and toxicity make new agents with high therapeutic indices desirable. Racemic cis-2',3'-dideoxy-5-fluoro-3'-thiacytidine (FTC)